BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 66 resultados LastUpdate Última actualización 14/10/2019 [17:27:00] pdf PDF xls XLS




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof

NºPublicación: AU2018239433A1 10/10/2019

Solicitante:
THE JACKSON LABORATORY
UNIV INDIANA RES & TECH CORP

Resumen de: AU2018239433A1

Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non- familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.



traducir


 

PEPTIDE OR COLLECTION OF PEPTIDES DERIVED FROM AMYLOID PRECURSOR PROTEIN

NºPublicación: US2019309035A1 10/10/2019

Solicitante:
LUDWIG MAXIMILIANS UNIV MUENCHEN [DE]
DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V [DE]

Resumen de: US2019309035A1

The present invention relates to a peptide or collection of peptides derived from amyloid precursor protein (APP). The present invention also relates to uses of such peptide or collection of peptides, in particular as a diagnostic marker and/or as a drug target.



traducir


 

USES OF CURCUMIN DERIVATIVE

NºPublicación: AU2019201665A1 10/10/2019

Solicitante:
MERRY LIFE BIOMEDICAL COMPANY LTD

Resumen de: AU2019201665A1

The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient. lNeuron NO, 02,(ROS) i Brain inflammation and tissue damage (atrophy) Cytokines o Microglia L4 activation Clearance [A1] Phagocytosis Microglia "-LgL Figure6/6 -6-



traducir


 

ALPHA-SYNUCLEIN DETECTION ASSAY AND METHOD FOR DIAGNOSING ALPHA-SYNUCLEINOPATHIES

NºPublicación: US2019302128A1 03/10/2019

Solicitante:
THE UNIV COURT OF THE UNIV OF EDINBURG [GB]

Resumen de: US2019302128A1

A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.



traducir


 

DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES

NºPublicación: US2019302125A1 03/10/2019

Solicitante:
ROWAN UNIV [US]

Resumen de: US2019302125A1

The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles.



traducir


 

METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND RISK OF PROGRESSION TO ALZHEIMER'S DISEASE

NºPublicación: US2019300960A1 03/10/2019

Solicitante:
LOMA LINDA UNIV HEALTH [US]

Resumen de: US2019300960A1

In one aspect, methods of diagnosing a subject as having Alzheimer's disease and prognosing a subject as being at risk of progressing to Alzheimer's disease are provided. In some embodiments, the method comprises determining one or more of the level of expression of rhotekin 2 (RTKN2), the level of expression of microtubule-associated Ser/Thr kinase 4 (MAST4), the level of binding of forkhead box O1 (FOXO1) to the RTKN2 promoter, and the level of binding of amyloid precursor protein (APP) to the MAST4 promoter in a sample from the subject.



traducir


 

METHODS OF USING AN ACTIVATOR OF CEREBLON FOR NEURAL CELL EXPANSION AND THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

NºPublicación: JP2019167381A 03/10/2019

Solicitante:
セルジーンコーポレイション

Resumen de: WO2015127351A1

Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (CNS) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (CRBN), such as an inhibitor of a CRBN substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into CNS cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. In certain embodiments, the methods further comprise differentiation of certain stem cells into the neural stem cells, neural progenitor cells, or neural precursor cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. Also provided herein, for example, are methods of preventing or treating a CNS cell defective disease, disorder or condition, or a symptom thereof, using a BRD7 antagonist, Ikaros antagonist, or CRBN activator.



traducir


 

CONFORMATIONAL MIMOTOPES FOR DETECTING SPECIFIC ANTIBODIES

NºPublicación: EP3545312A1 02/10/2019

Solicitante:
DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S C A R L [IT]

Resumen de: WO2018096512A1

The present invention relates to a method for obtaining protein mimotopes occurring in at least two distinct 3D conformations. In a further embodiment, a method for detecting antibodies with diagnostic relevance using said mimotopes is claimed. In a preferred embodiment, said methods are applied to Alzheimer's disease.



traducir


 

ANTI-PHF-TAU ANTIBODIES AND USES THEREOF

NºPublicación: SG11201907754RA 27/09/2019

Solicitante:
JANSSEN BIOTECH INC [US]

Resumen de: SG11201907754RA

Comparisonof Recombinant PT to Purified, Hybridoma Derived PT3 . ePHF and Soluble Tau Binding 1.2 0:8 - ----ePHF - R3788 ePHF -hyb PT3 soluble - R3788 - soluble - hyb PT3 .17.4 O 0 0 LC, LX) O 0 LC, C, LV O LC/ CV CO CO CO 0, LO Cv: n mL E O 0.6 0.4 0.2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT °Ens °nolo olomonomu Imo oimIE (10) International Publication Number WO 2018/170351 Al (51) International Patent Classification: C07K 16/00 (2006.01) (21) International Application Number: PCT/US2018/022782 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,214 16 March 2017 (16.03.2017) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: MERCKEN, Marc; Turnhoutseweg 30, 2340 Beerse (BE). MALIA, Thomas; 825 N. 29th St., Philadel- phia, Pennsylvania 19130 (US). BORGERS, Marianne; Turnhoutseweg 30, 2340 Beerse (BE). VAN KOLEN, Kristof; Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB,



traducir


 

METHOD FOR JUDGING PSYCHIATRIC DISORDER

NºPublicación: WO2019181830A1 26/09/2019

Solicitante:
FUJIFILM WAKO PURE CHEMICAL CORP [JP]

Resumen de: WO2019181830A1

The present invention addresses the problem of providing a highly exact (accurate and precise) method for judging a psychiatric disorder such as depressive disorder, bipolar disorder, schizophrenia or dementia. The present invention pertains to a method for judging a psychiatric disorder, a marker for judging a psychiatric disorder, etc.



traducir


 

Uses of Curcumin Derivative

NºPublicación: US2019290604A1 26/09/2019

Solicitante:
MERRY LIFE BIOMEDICAL COMPANY LTD [TW]

Resumen de: US2019290604A1

The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient.



traducir


 

ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THAT SPECIFICALLY BIND TO MICROTUBULE-ASSOCIATED PROTEIN TAU

NºPublicación: US2019292249A1 26/09/2019

Solicitante:
JANSSEN VACCINES & PREVENTION BV [NL]

Resumen de: US2019292249A1

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.



traducir


 

IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS

NºPublicación: JP2019163268A 26/09/2019

Solicitante:
ニューヨーク・ユニバーシティ

Resumen de: US2010316564A1

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.



traducir


 

COMBINED ASSAY FOR THE DIFFERENTIAL DIAGNOSIS OF THE ALZHEIMER'S DISEASE

NºPublicación: EP3542165A1 25/09/2019

Solicitante:
RUHR UNIV BOCHUM [DE]

Resumen de: EP3324187A1

The invention provides a combined immuno-infrared assay for the differential diagnosis and sub classification of Alzheimer's disease into different disease stages. The method can be applied for assured disease diagnostics and patient stratification. The assay considers the label-free detection of the change within the Amyloid-beta peptide and Tau protein secondary structure distribution in bodily fluids. This secondary structure change from native to ß-sheet enriched isoforms appears years before clinical disease manifestation. Now, the combined method utilizes this shift for diagnostics based on liquid biopsies.



traducir


 

METHOD FOR THE PRESELECTION OF DRUGS FOR PROTEIN MISFOLDING DISEASES

NºPublicación: EP3542164A1 25/09/2019

Solicitante:
RUHR UNIV BOCHUM [DE]

Resumen de: EP3324186A1

The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a target biomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.



traducir


 

Uses of curcumin derivative

NºPublicación: GB2572259A 25/09/2019

Solicitante:
MERRY LIFE BIOMEDICAL COMPANY LTD [TW]

Resumen de: GB2572259A

Curcumin derivative TML-6, having the following structure: or a pharmaceutically acceptable salt, solvate, hydrate, isotopologue, or prodrug thereof, and optionally a pharmaceutically acceptable carrier or excipient, for use in a method of preventing and/or treating Alzheimer’s disease in a subject in need of such treatment, said method comprising administering to said subject an effective amount of TML-6 or said salt, solvate, hydrate, isotopologue, or prodrug thereof and optionally said pharmaceutically acceptable carrier or excipient. Curcumin derivative TML-6 is a (1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione wherein the 4 position is substituted with a methyl group and N,N-diethylacetamide. TML-6 may increase apolipoprotein E (ApoE) expression, promote beta-amyloid clearance, inhibit amyloid precursor protein synthesis and/or inhibit inflammation in brain regions, particularly the hippocampus and other frontal regions. A method of identifying a candidate compound which may increase apolipoprotein E expression, promote beta-amyloid clearance, inhibit amyloid precursor protein synthesis and/or inhibit inflammation in brain regions, comprises contacting the candidate compound with AP-2 or PPARα/RXRα binding site of ApoE promoter region and determining if the candidate compound binds to AP-2 or PPARα/RXRα binding site of ApoE promoter region.



traducir


 

USE OF CYTOKINE LEVELS IN INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación: BR112013025197A2 24/09/2019

Solicitante:
BAXTER HEALTHCARE SA [CH]
BAXTER INT [US]

Resumen de: WO2012135752A1

The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided. Preferably, the therapeutic agent is an intravenous immunoglobulin (IVIG) composition.



traducir


 

CD44 SPLICE VARIANTS IN NEURODEGENERATIVE DISEASES

NºPublicación: BRPI0814685A2 24/09/2019

Solicitante:
NEURIN PHARMACEUTICALS 1991 LTD [IL]

Resumen de: WO2009007934A2

There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof.



traducir


 

ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)

NºPublicación: BRPI0911073A2 24/09/2019

Solicitante:
BLANCHETTE ROCKEFELLER NEUROSCIENCES INST [US]

Resumen de: WO2009126232A1

The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease- specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.



traducir


 

METHOD FOR SELECTIVELY QUANTIFYING A-BETA AGGREGATES

NºPublicación: BR112014015392A2 24/09/2019

Solicitante:
FORSCHUNGSZENTRUM JUELICH GMBH [DE]

Resumen de: WO2013092952A2

The invention relates to methods for selectively quantifying a-beta aggregates, comprising the immobilization of anti a-beta antibodies on a substrate, the application of the sample to be examined on the substrate, the addition of probes marked for detection, which mark said probes by specific binding to a-beta aggregates, and the detection of the marked aggregates.



traducir


 

STANDARD FOR QUANTIFYING PATHOGENIC AGGREGATES FROM PROTEINS PRODUCED NATURALLY IN THE BODY

NºPublicación: BR112014015397A2 24/09/2019

Solicitante:
FORSCHUNGSZENTRUM JUELICH GMBH [DE]

Resumen de: WO2013092951A2

The invention relates to standards for quantifying pathogenic aggregates or oligomers from proteins produced naturally in the body, which characterize a protein aggregation disease, an amyloid degeneration or protein folding aberration diseases, and to the use of said standards for quantifying said pathogenic aggregates or oligomers.



traducir


 

USES OF CURCUMIN DERIVATIVE

NºPublicación: CA3036444A1 23/09/2019

Solicitante:
MERRY LIFE BIOMEDICAL COMPANY LTD [CN]

Resumen de: CA3036444A1

The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient.



traducir


 

METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

NºPublicación: KR20190108118A 23/09/2019

Solicitante:
유마니티테라퓨틱스인크

Resumen de: US2018193325A1

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.



traducir


 

Personalized Healthcare P4 Alzheimer's Detection System and Method

NºPublicación: US2019284631A1 19/09/2019

Solicitante:
ENANO HEALTH LTD [HK]

Resumen de: US2019284631A1

The claimed invention provides real-time and subsequent analysis personalized user based health and wellness information for predictive Alzheimer's diagnosis information. Non-invasive techniques utilize saliva for body levels of wellness indicators and microRNA predictive markers which are coordinated over time. Saliva captured on lateral flow sample collection strips are real-time indicator reviewed and subsequently analyzed using optional traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated with time of administration with genetic sequence analysis to confirm related disease conditions. By using P4 (Participatory, Personalized, Predictive, and Preventive) health management techniques the patient determines if telltale correlative microRNA indicators are present.



traducir


 

MARKERS OF SYNAPTOPATHY IN NEURODEGENERATIVE DISEASE

Nº publicación: WO2019175379A1 19/09/2019

Solicitante:
FUNDACIO INST DE RECERCA DE LHOSPITAL DE LA SANTA CREU I SANT PAU [ES]

Resumen de: WO2019175379A1

The present invention provides in vitro methods for the diagnosis and/or prognosis of synaptopathy and/or neurodegeneration in an individual, for deciding whether to initiate a therapeutic intervention, and for monitoring the efficacy of the therapeutic intervention, all based on the determination of the level of product expression of VAMP-2and/or Syntaxin-1.Advantageously, these markers allow the early detection of synaptopathy in diseases such as Alzheimer's disease.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver